Everpar Advisors LLC Decreases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Everpar Advisors LLC lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 26.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 693 shares of the pharmaceutical company’s stock after selling 244 shares during the quarter. Everpar Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $322,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in VRTX. Capital World Investors lifted its holdings in shares of Vertex Pharmaceuticals by 17.2% during the 1st quarter. Capital World Investors now owns 25,567,184 shares of the pharmaceutical company’s stock valued at $10,687,339,000 after purchasing an additional 3,761,414 shares during the last quarter. Capital Research Global Investors raised its stake in Vertex Pharmaceuticals by 61.0% in the 1st quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company’s stock worth $2,401,000,000 after acquiring an additional 2,176,218 shares during the last quarter. Jennison Associates LLC raised its stake in Vertex Pharmaceuticals by 21.2% in the 1st quarter. Jennison Associates LLC now owns 4,782,374 shares of the pharmaceutical company’s stock worth $1,999,080,000 after acquiring an additional 837,461 shares during the last quarter. Swedbank AB purchased a new position in Vertex Pharmaceuticals in the 1st quarter worth $277,317,000. Finally, AMF Tjanstepension AB purchased a new position in Vertex Pharmaceuticals in the 2nd quarter worth $257,655,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $487.34, for a total value of $1,111,135.20. Following the sale, the chief marketing officer now owns 27,819 shares of the company’s stock, valued at $13,557,311.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $487.34, for a total transaction of $1,111,135.20. Following the completion of the transaction, the chief marketing officer now owns 27,819 shares in the company, valued at approximately $13,557,311.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the transaction, the director now owns 4,435 shares of the company’s stock, valued at approximately $2,217,500. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,767 shares of company stock valued at $15,768,284 over the last quarter. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Trading Down 1.5 %

VRTX opened at $448.60 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. The company’s 50 day simple moving average is $476.75 and its two-hundred day simple moving average is $455.91. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $510.64. The firm has a market capitalization of $115.76 billion, a price-to-earnings ratio of 29.14 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The firm had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.53 EPS. Analysts expect that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of research analyst reports. Argus raised their target price on Vertex Pharmaceuticals from $465.00 to $550.00 and gave the stock a “buy” rating in a research note on Monday, June 17th. Royal Bank of Canada reduced their target price on Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating for the company in a research note on Friday. TD Cowen raised their target price on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Piper Sandler lifted their price objective on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Canaccord Genuity Group lifted their price objective on Vertex Pharmaceuticals from $371.00 to $376.00 and gave the company a “sell” rating in a research note on Wednesday, July 31st. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Hold” and an average target price of $486.95.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.